Andrea Szentesi

Dr. Andrea Szentesi


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Peter HegyiPeter Hegyi
Peter Hegyi
BEBalint Eross
Balint Eross
FIFerenc Izbeki
Ferenc Izbeki
APAndrea Párniczky
Andrea Párniczky
ASAndrea Szentesi
Andrea Szentesi

19 July 2020 in Obesity Reviews
Verified
Journal Article
Open access
PDF file
MFMária Földi
Mária Földi
NFNelli Farkas
Nelli Farkas
SKSzabolcs Kiss
Szabolcs Kiss
NZNoémi Zádori
Noémi Zádori
SVSzilárd Váncsa
Szilárd Váncsa
KGKETLAK Study Group
KETLAK Study Group
Summary: The disease course of COVID‐19 varies from asymptomatic infection to critical condition leading to mortality. Identification of prognostic factors is important for prevention and early treatment. We aimed to examine whether obesity is a risk factor for the critical condition in COVID‐19 patients by performing a meta‐analysis. The review protocol was registered onto PROSPERO (CRD42020185980). A systematic search was performed in five scientific databases between 1 January and 11 May 2020. After selection, 24 retrospective cohort studies were included in the qualitative and quantitative analyses. We calculated pooled odds ratios (OR) with 95% confidence intervals (CIs) in meta‐analysis. Obesity was a significant risk factor for intensive care unit (ICU) admission in a homogenous dataset (OR = 1.21, CI: 1.002‐1.46; I2 = 0.0%) as well as for invasive mechanical ventilation (IMV) (OR = 2.05, CI: 1.16‐3.64; I2 = 34.86%) in COVID‐19. Comparing body mass index (BMI) classes with each other, we found that a higher BMI always carries a higher risk. Obesity may serve as a clinical predictor for adverse outcomes; therefore, the inclusion of BMI in prognostic scores and improvement of guidelines for the intensive care of patients with elevated BMI are highly recommended.

Verified
Journal Article
Open access
PDF file
Peter HegyiPeter Hegyi
Peter Hegyi
OPOle Petersen
Ole Petersen
SHStephen Holgate
Stephen Holgate
BEBalint Eross
Balint Eross
Andras GaramiAndras Garami
Andras Garami
ASAndrea Szentesi
Andrea Szentesi
Introduction: Translational science has gained prominence in medicine, but there is still much work to be done before scientific results are used optimally and incorporated into everyday health practice. As the main focus is still on generating new scientific data with financial resources primarily available for that purpose, other activities that are necessary in the transition from research to community benefit are considered less needy. The European Statistical Office of the European Commission has recently reported that 1.7 million people under 75 years of age died in Europe in 2016, with around 1.2 million of those deaths being avoidable through effective primary prevention and public health intervention. Therefore, Academia Europaea, one of the five Pan-European networks that form SAPEA (Science Advice for Policy by European Academies), a key element of the European Commission’s Scientific Advice Mechanism (SAM), has launched a project to develop a model to facilitate and accelerate the utilisation of scientific knowledge for public and community benefit. Methods: During the process, leaders in the field, including prominent basic and clinical researchers, editors-in-chief of high-impact journals publishing translational research articles, translational medicine (TM) centre leaders, media representatives, academics and university leaders, developed the TM cycle, a new model that we believe could significantly advance the development of TM. Results: This model focuses equally on the acquisition of new scientific results healthcare, understandable and digestible summation of results, and their communication to all participants. We have also renewed the definition in TM, identified challenges and recommended solutions. Conclusion: The authors, including senior officers of Academia Europaea, produced this document to serve as a basis for revising thinking on TM with the end result of enabling more efficient and cost-effective healthcare.

1 June 2020 in Pancreatology
Verified
Journal Article
Open access
DMDóra Mosztbacher
Dóra Mosztbacher
LHLilla Hanák
Lilla Hanák
NFNelli Farkas
Nelli Farkas
ASAndrea Szentesi
Andrea Szentesi
AMAlexandra Mikó
Alexandra Mikó
Peter HegyiPeter Hegyi
Peter Hegyi
Hypertriglyceridemia is the third most common cause of acute pancreatitis (AP). It has been shown that hypertriglyceridemia aggravates the severity and related complications of AP; however, detailed analyses of large cohorts are contradictory. Our aim was to investigate the dose-dependent effect of hypertriglyceridemia on AP. AP patients over 18 years old who underwent triglyceride measurement within the initial three days were included into our cohort analysis from a prospective international, multicenter AP registry operated by the Hungarian Pancreatic Study Group. Data on 716 AP cases were analyzed. Six groups were created based on the highest triglyceride level (<1.7 mmol/l, 1.7-2.19 mmol/l, 2.2-5.59 mmol/l, 5.6-11.29 mmol/l, 11.3-22.59 mmol/l, ≥22.6 mmol/l). Hypertriglyceridemia (≥1.7 mmol/l) presented in 30.6% of the patients and was significantly and dose-dependently associated with younger age and male gender. In 7.7% of AP cases, hypertriglyceridemia was considered as a causative etiological factor (≥11.3 mmol/l); however, 43.6% of these cases were associated with other etiologies (alcohol and biliary). Hypertriglyceridemia was significantly and dose-dependently related to obesity and diabetes. The rates of local complications and organ failure and maximum CRP level were significantly and dose-dependently raised by hypertriglyceridemia. Triglyceride above 11.3 mmol/l was linked to a significantly higher incidence of moderately severe AP and longer hospital stay, whereas triglyceride over 22.6 mmol/l was significantly associated with severe AP as well. Hypertriglyceridemia dose-dependently aggravates the severity and related complications of AP. Diagnostic workup for hypertriglyceridemia requires better awareness regardless of the etiology of AP.

1 June 2019 in Pancreatology
Verified
Journal Article
Open access
APAndrea Párniczky
Andrea Párniczky
Tamás LantosTamás Lantos
Tamás Lantos
ETEszter Margit Tóth
Eszter Margit Tóth
ZSZsolt Szakács
Zsolt Szakács
SGSzilárd Gódi
Szilárd Gódi
Peter HegyiPeter Hegyi
Peter Hegyi
Unwarranted administration of antibiotics in acute pancreatitis presents a global challenge. The clinical reasoning behind the misuse is poorly understood. Our aim was to investigate current clinical practices and develop recommendations that guide clinicians in prescribing antibiotic treatment in acute pancreatitis. Four methods were used. 1) Systematic data collection was performed to summarize current evidence; 2) a retrospective questionnaire was developed to understand the current global clinical practice; 3) five years of prospectively collected data were analysed to identify the clinical parameters used by medical teams in the decision making process, and finally; 4) the UpToDate Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was applied to provide evidence based recommendations for healthcare professionals. The systematic literature search revealed no consensus on the start of AB therapy in patients with no bacterial culture test. Retrospective data collection on 9728 patients from 22 countries indicated a wide range (31-82%) of antibiotic use frequency in AP. Analysis of 56 variables from 962 patients showed that clinicians initiate antibiotic therapy based on increased WBC and/or elevated CRP, lipase and amylase levels. The above mentioned four laboratory parameters showed no association with infection in the early phase of acute pancreatitis. Instead, procalcitonin levels proved to be a better biomarker of early infection. Patients with suspected infection because of fever had no benefit from antibiotic therapy. The authors formulated four consensus statements to urge reduction of unjustified antibiotic treatment in acute pancreatitis and to use procalcitonin rather than WBC or CRP as biomarkers to guide decision-making.

14 February 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DDDalma Dobszai
Dalma Dobszai
PMPéter Mátrai
Péter Mátrai
ZGZoltán Gyöngyi
Zoltán Gyöngyi
Dezső CsuporDezső Csupor
Dezső Csupor
JBJudit Bajor
Judit Bajor
OGon behalf of the Hungarian Pancreatic Study Group
on behalf of the Hungarian Pancreatic Study Group
Body-mass index correlates with severity and mortality in acute pancreatitis: A meta-analysis